New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 11, 2012
12:09 EDTVRTXVertex presents new Phase 3 data on HCV treatment with twice-daily telaprevir
Vertex Pharmaceuticals announced that new data from a Phase 3 study in people being treated for hepatitis C for the first time showed similar rates of viral cure (SVR12, HCV RNA levels < 25 IU/mL 12 weeks after the end of all treatment) when telaprevir was given twice daily compared to three times daily, the currently approved dosing schedule. Telaprevir is approved for use in combination with pegylated-interferon and ribavirin by the U.S. Food and Drug Administration, FDA, and Health Canada under the brand name INCIVEK® (telaprevir) tablets for people with genotype 1 chronic hepatitis C virus, HCV, with compensated liver disease (some level of damage to the liver but the liver still functions), including cirrhosis (scarring of the liver). In addition, new data from a Phase 2 study demonstrated that approximately three of four people co-infected with HCV and HIV achieved an HCV viral cure (SVR24, HCV RNA levels < 25 IU/mL 24 weeks after the end of all treatment) with telaprevir combination treatment. These and other new data on Vertex’s medicines in development for hepatitis C were presented at The Liver Meeting®, the 63rd Annual Meeting of the American Association for the Study of Liver Diseases, AASLD.
News For VRTX From The Last 14 Days
Check below for free stories on VRTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2014
14:04 EDTVRTXWorldwide Business Research to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use